Request Demo
Last update 13 Dec 2025
Recombinant anti-CD73 fully human monoclonal antibody (Henlix Biotech)
Last update 13 Dec 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms HLX-23 |
Target |
Action inhibitors |
Mechanism CD73 inhibitors(5-nucleotidase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with Recombinant anti-CD73 fully human monoclonal antibody (Henlix Biotech)NCT04797468
A Phase 1 Clinical Study to Investigate the Safety, Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of HLX23 (CD73 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors
100 Clinical Results associated with Recombinant anti-CD73 fully human monoclonal antibody (Henlix Biotech)
Login to view more data
100 Translational Medicine associated with Recombinant anti-CD73 fully human monoclonal antibody (Henlix Biotech)
Login to view more data
100 Patents (Medical) associated with Recombinant anti-CD73 fully human monoclonal antibody (Henlix Biotech)
Login to view more data
100 Deals associated with Recombinant anti-CD73 fully human monoclonal antibody (Henlix Biotech)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | United States | 18 Jul 2022 | |
| Metastatic Solid Tumor | Phase 1 | United States | 18 Jul 2022 | |
| Lymphoma | IND Approval | China | 17 Jan 2023 | |
| Solid tumor | IND Approval | China | 17 Jan 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free